Skip to main content

Sana Biotechnology

Sana Biotechnology Inc is an American clinical-stage biopharmaceutical company developing engineered cell therapies for oncology, autoimmune diseases, and diabetes. The company advances its proprietary Hypoimmune (HIP) platform to escape immune rejection alongside fusogen technology for targeted cell delivery, advancing candidates including SC291 (CD19-targeted CAR-T) and UP421 (allogeneic islet cell therapy). Main revenue drivers currently consist of investment capital financing, research partnership receipts, and potential milestone licensing revenues as clinical trials progress. Sana Biotechnology targets medical oncologists, endocrinologists, clinical research hospitals, and patients across North America and Europe. The company holds an innovative market position in hypoimmune engineered cell therapy and targeted fusogen delivery technology. Headquartered in Seattle, Washington, Sana Biotechnology Inc is listed on the Nasdaq Stock Market.

2 of the funds FundTelligence covers report a position in Sana Biotechnology.

Legal name
SANA BIOTECHNOLOGY INC
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Sana Biotechnology

Loading...